Use of selpercatinib in a patient with <i>RET</i>-mutated non-small cell lung cancer: case report
Background. The use of the modern targeted drugs in patients with non-small-cell lung cancer (NSCLC) with certain somatic alterations (genetic alterations in EGFR, ALK, ROS1, BRAF, RET genes, etc.) provides a significant increase in overall and disease-free survival with an acceptable toxicity profi...
Saved in:
| Main Authors: | A. M. Kazakov, K. K. Laktionov, V. O. Vorobyeva, K. A. Sarantseva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2024-05-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/3049 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01) -
Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report
by: Illaa Smesseim, MD, et al.
Published: (2024-12-01) -
Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case
by: Raffaella Pagliaro, et al.
Published: (2025-01-01) -
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors
by: Daniela Esposito, et al.
Published: (2025-05-01) -
First-line selpercatinib for a patient with RET fusion-positive pulmonary large cell neuroendocrine carcinoma
by: Tatsuru Eihuku, et al.
Published: (2024-01-01)